RT Journal Article
SR Electronic
T1 Launching a saliva-based SARS-CoV-2 surveillance testing program on a university campus
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.24.21250385
DO 10.1101/2021.01.24.21250385
A1 Ehrenberg, Alexander J.
A1 Moehle, Erica A.
A1 Brook, Cara E.
A1 Doudna Cate, Andrew H.
A1 Witkowsky, Lea B.
A1 Sachdeva, Rohan
A1 Hirsh, Ariana
A1 Barry, Kerrie
A1 Hamilton, Jennifer R.
A1 Lin-Shiao, Enrique
A1 McDevitt, Shana
A1 Valentin-Alvarado, Luis
A1 Letourneau, Kaitlyn N.
A1 Hunter, Lauren
A1 Keller, Amanda
A1 Pestal, Kathleen
A1 Frankino, Phillip A.
A1 Murley, Andrew
A1 Nandakumar, Divya
A1 Stahl, Elizabeth C.
A1 Tsuchida, Connor A.
A1 Gildea, Holly K.
A1 Murdock, Andrew G.
A1 Hochstrasser, Megan L.
A1 O’Brien, Elizabeth
A1 Ciling, Alison
A1 Tsitsiklis, Alexandra
A1 Worden, Kurtresha
A1 Dugast-Darzacq, Claire
A1 Hays, Stephanie G.
A1 Barber, Colin C.
A1 McGarrigle, Riley
A1 Lam, Emily
A1 Ensminger, David
A1 Bardet, Lucie
A1 Sherry, Carolyn
A1 ,
A1 Harte, Anna
A1 Nicolette, Guy
A1 Giannikopoulos, Petros
A1 Hockemeyer, Dirk
A1 Petersen, Maya
A1 Urnov, Fyodor D.
A1 Ringeisen, Bradley R.
A1 Boots, Mike
A1 Doudna, Jennifer A.
YR 2021
UL http://medrxiv.org/content/early/2021/01/30/2021.01.24.21250385.abstract
AB Regular surveillance testing of asymptomatic individuals for SARS-CoV-2 has played a vital role in SARS-CoV-2 outbreak prevention on college and university campuses. Here we describe the voluntary saliva testing program instituted at the University of California, Berkeley during an early period of the SARS-CoV-2 pandemic in 2020. The program was administered as a research study ahead of clinical implementation, enabling us to launch surveillance testing while continuing to optimize the assay. Results of both the testing protocol itself and the study participants’ experience show how the program succeeded in providing routine, robust testing capable of contributing to outbreak prevention within a campus community and offer strategies for encouraging participation and a sense of civic responsibility.Competing Interest StatementThe Regents of the University of California have patents issued and pending for CRISPR technologies on which J.A.D. is an inventor. J.A.D. is a co-founder of Caribou Biosciences, Editas Medicine, Scribe Therapeutics, Intellia Therapeutics, and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Mammoth Biosciences, Synthego, Algen Biotechnologies, Felix Biosciences, and Inari. J.A.D. is a Director at Johnson & Johnson and has research projects sponsored by Biogen, Pfizer, AppleTree Partners, and Roche. F.D.U. is a co-founder of Tune Therapeutics. P.G. is a co-founder and Director at NewCo Health. P.G. is the CLIA Laboratory Director for Coral Genomics and 3DMed. The other authors declare no competing interests.Funding StatementWe thank the Packard Foundation, the Curci Foundation, the Julia Burke Foundation, and other anonymous donors for their support of IGI FAST. We additionally thank the University of California, Berkeley for their financial support of IGI FAST. A.J.E. is a graduate research fellow at the Greater Good Science Center at the University of California, Berkeley. J.R.H. is a Fellow of The Jane Coffin Childs Memorial Fund for Medical Research. A.M. is a fellow of the Damon Runyon Cancer Research Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of California, Berkeley Committee for Protection of Human Subjects IRB #2020-05-13336All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data included in this article and the supplementary files are available upon request to the corresponding authors.